Kairos Pharma Reports Promising Interim Phase 2 Results for ENV105 in Prostate Cancer Treatment

Kairos Pharma Ltd. (NYSE American: KAPA) announced positive interim efficacy data from its ongoing Phase 2 trial of ENV105 (carotuximab) in metastatic castration-resistant prostate cancer. The clinical-stage biopharmaceutical company reported that among eight evaluable patients, the ENV105 and apalutamide combination achieved median progression-free survival of more than 13 months, with five patients still on treatment and seven of nine showing declines in prostate-specific antigen levels.

This result significantly exceeded the trial's target of a 45% improvement in progression-free survival compared with the standard 3.7 months for second- or third-line hormone therapy. The treatment demonstrated a favorable safety profile, being well tolerated with no dose-limiting toxicities observed during the study period. The combination therapy's performance suggests potential for addressing the significant unmet medical needs in advanced prostate cancer treatment.

ENV105 is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy often results in resistance and disease relapse. By targeting CD105, ENV105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. The company is currently conducting additional clinical trials, including a Phase 1 trial for lung cancer, further exploring ENV105's potential applications.

The positive interim data could have substantial implications for prostate cancer treatment paradigms. Metastatic castration-resistant prostate cancer represents an advanced stage of the disease where treatment options are limited and outcomes are typically poor. The demonstrated progression-free survival extension to more than 13 months, compared to the historical standard of 3.7 months, suggests ENV105 may offer a meaningful clinical benefit for patients who have exhausted other treatment options.

For the biotechnology industry, these results highlight the potential of targeting resistance mechanisms in cancer treatment. The approach of combining novel agents with existing standard therapies to overcome resistance represents an important strategy in oncology drug development. Success in this area could pave the way for similar combination approaches in other cancer types where treatment resistance remains a significant challenge.

Additional information about Kairos Pharma and its development programs is available in the company's newsroom at https://ibn.fm/KAPA. The company hosted a webcast with clinical experts to review these findings, providing further context for the medical community and investors interested in the advancement of prostate cancer treatments.